Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
Summary
The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.
Detailed description
Patients who cannot undergo surgical resection for either breast cancer or local control of metastatic cancer have limited effective treatment options. Treatments typically employed in the adjuvant setting have been found in the definitive setting to be inferior to surgery followed by adjuvant therapy. This raises the necessity of evaluating the use of ablative doses of radiation to provide durable local control of the tumor in such patients. Indeed, there is growing evidence that RT is effective in the adjuvant setting. This is a study of concurrent ultra-hypofractionated whole breast whole breast radiation delivered via simultaneous integrated boost to the gross tumor for breast cancer patients not undergoing surgery.
Arms & interventions
- RadiationWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor
Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
- RadiationWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes
Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions
Outcome measures
Primary
Treatment Safety
Incidence of physician-assessed treatment-related toxicity ≥ Grade 4 events, as defined using CTCAE 5.0
Time frame: 12 months
Secondary
Acute Toxicity
Time frame: 12 months
Late Toxicity
Time frame: 5 years
Treatment Tolerability by EORTC QLQ-C30
Time frame: 2 years
Treatment Tolerability by EORTC QLQ-BR42
Time frame: 2 years
Tumor Response Rate in the Gross Disease Volume (40Gy)
Time frame: 1 year
Progression Free Rate in the Microscopic Disease Volume (26Gy)
Time frame: 1 year
Clinical Response in patients with Palpable Disease
Time frame: 1 year
Eligibility criteria
Study locations (1)
Stony Brook University Cancer Center
Stony Brook, New York, 11794